Phase I/II Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Jul 2018
At a glance
- Drugs Bendamustine (Primary) ; Ixazomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 16 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 May 2020.
- 29 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 29 Jan 2018 Status changed from recruiting to active, no longer recruiting.